ABSTRACT
The human gut hosts an array of bacteria that conduct many immune and metabolic functions. The co-evolution to the immune system and microbes of the gut is the topic of interest for cancer and nutraceutical research. The environmental and biological factors that impact gut diversity can also lead to the development of intestinal dysbiosis. The developing microbiota of the human gut up until the age of 2 exhibits relatively low diversity, low stability, and more vigor compared to adult microbiota. While the diversity of the infant microbiota can initially resemble the composition of the birth mother’s microbiota due to vertical transmission of bacteria from mother to infant, the overall anatomy of the gut is individualized. In carcinogenesis, dysfunction of cell growth and suppression of the apoptotic pathway are both required for cancer formation. Nutraceuticals are alternative therapeutic agents to control the progression of cancer by promoting normal cells function, regulating tumor suppressor genes and bolstering the immune system.
